Tempest Therapeutics Inc. stocks have been trading up by 39.0 percent amid strong sentiment from its most recent clinical trial news
Click Here for a Millionaire's POV on Trading TPST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Tempest Therapeutics entered an exclusive option deal with Hebei Senlang for a CD7-targeted lentiviral in vivo CAR-T platform and multiple early oncology/autoimmune programs.
- Shares of TPST spiked about 35% after-hours as Tempest Therapeutics paired the Senlang option with a roughly $2.5M warrant-based private placement.
- The Senlang clinical-stage BCMA/GPRC5D dual-targeting multiple myeloma program would sit alongside Tempest Therapeutics’ own CD7-targeted LNP in vivo CAR-T platform.
- Management plans to spotlight TPST-4003 and the broader in vivo CAR-T pipeline at the H.C. Wainwright 28th Annual Global Investment Conference.
Live Update At 07:46:54 EDT: On Wednesday, September 16, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending up by 39.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TPST is still a tiny biotech trying to push high-risk science with a thin balance sheet, and the numbers show it clearly. For the quarter ended 2026/06/30, Tempest Therapeutics posted a net loss of about $5.24M, or roughly -$0.34 per share. Operating cash flow was around -$2.78M, leaving the company with just about $1.22M in cash at quarter-end. That is not much runway.
The balance sheet for Tempest Therapeutics shows total assets of $9.63M against total liabilities of $10.72M, with stockholders’ equity sitting at roughly -$1.09M. A current ratio of 0.4 and quick ratio of 0.2 tell traders that TPST is tight on near-term liquidity. Long-term debt of about $6.27M keeps financial pressure elevated.
More Breaking News
- Akamai Stock Surges As Anthropic AI Megadeal Re-Rates The Story
- VIAV Stock Climbs As Defense Certification And AI Data Center Push Energize Traders
- MGLD Stock Trades In Tight Range As Losses Persist
- QBTS Stock Pops As D-Wave Quantum Strikes CGI Partnership
On the market side, TPST has been sliding for weeks. The daily chart shows the stock drifting from the $1.10–$1.14 area down into the mid-$0.70s, a clear downtrend into the latest news. Intraday data show sharp spikes and fades between $1.15 and $1.34, classic thin-float biotech action. For traders, Tempest Therapeutics is a story of explosive headline-driven moves layered on top of a fragile financial base.
Why Traders Are Watching TPST Now
Traders are crowding into TPST because the story just got a lot bigger, even if the fundamentals are still early-stage. Tempest Therapeutics locked in an exclusive option with Hebei Senlang Biotechnology for a CD7-targeted lentiviral in vivo CAR-T platform and a portfolio of candidates. That includes a Phase 1 BCMA/GPRC5D dual-targeting CAR-T for relapsed or refractory multiple myeloma and other blood and autoimmune diseases.
For a micro-cap like Tempest Therapeutics, access to a clinical-stage, dual-target asset under an option structure is a big narrative upgrade. It lets TPST talk about real patients and ongoing dose escalation, not just preclinical slides. At the same time, the company raised about $2.5M through a warrant-based private placement, which helped spark a 35% after-hours surge in the stock. The raise is small, but it buys a bit more time.
The key angle for traders is strategy. Tempest Therapeutics already has its own CD7-targeted LNP in vivo CAR-T platform. Adding Senlang’s lentiviral in vivo CAR-T platform means TPST is trying to build an “immune reset” franchise that attacks hematologic cancers and autoimmune disease from multiple technology angles. If the science keeps lining up, this gives TPST a differentiated story versus one-trick CAR-T names.
On top of that, Tempest Therapeutics will hit the stage at the H.C. Wainwright 28th Annual Global Investment Conference to highlight its in vivo CAR-T platform and lead candidate TPST-4003. Conferences like this often act as short-term catalysts. Traders watch for new data tidbits, slide decks, and fresh eyeballs on the name, especially when the chart has already shown it can move 30%+ on headlines.
Conclusion
TPST is now a classic high-risk, high-volatility biotech trade. The Tempest Therapeutics deal with Hebei Senlang gives the company an exclusive option to a CD7-targeted lentiviral in vivo CAR-T platform plus a Phase 1 BCMA/GPRC5D program, extending its reach in multiple myeloma and autoimmune disease. That news, paired with the roughly $2.5M private placement, was enough to rip TPST about 35% after-hours and put the ticker back on traders’ scanners.
But the financials behind Tempest Therapeutics remain tight. Negative equity, limited cash, and ongoing quarterly burns near $2.8M in operating cash flow mean TPST is always one step away from needing more capital. That tension between ambitious pipeline expansion and balance-sheet strain is exactly what creates the big trading swings.
For short-term players, the setup is clear: Tempest Therapeutics has fresh news, a compelling in vivo CAR-T “immune reset” angle, and an upcoming H.C. Wainwright conference where management will talk up TPST-4003 and the enlarged platform. That combination often feeds momentum and squeezes. In this kind of volatile environment, it helps to remember the core trading checklist: as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. Just remember what Tim Sykes pounds into his students: “The best traders are cowards — they cut losses quickly and never fall in love with a story.” TPST offers a powerful story, but disciplined trading — not hope — has to drive every decision.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.